Mitragynine

Mitragynine is the primary psychoactive alkaloid found in kratom (Mitragyna speciosa), accounting for up to 66% of the plant's alkaloid content. It acts as a partial agonist at mu-opioid receptors while also interacting with adrenergic and serotonergic pathways.

Origin & History

Mitragynine is the primary alkaloid found in the leaves of Mitragyna speciosa (kratom), a tropical tree native to Southeast Asia. It belongs to the indole alkaloid chemical class, specifically a Corynanthe-type alkaloid, and is typically extracted from kratom leaves via solvent-based methods followed by purification.

Historical & Cultural Context

Mitragynine from kratom leaves has been used in Southeast Asian traditional medicine (Thai and Malaysian folk systems) for centuries to manage pain, opioid withdrawal, and fatigue. Historical use includes both stimulant effects at low doses and sedative effects at high doses.

Health Benefits

• May support pain management (preclinical evidence only - no human controlled studies available)
• Potential for opioid withdrawal support (traditional use reported, but no clinical trials conducted)
• Possible mood and impulsivity effects (phase 1 trial showed slight increases in impulsivity measures at higher doses)
• May influence blood pressure (phase 1 trial showed minor reductions in systolic/diastolic blood pressure)
• Traditional use for fatigue management (historical evidence only - no clinical validation)

How It Works

Mitragynine functions as a partial agonist at mu-opioid receptors (MOR) and delta-opioid receptors, producing analgesic effects without full opioid receptor activation. It also modulates alpha-2 adrenergic receptors and 5-HT2A serotonin receptors, contributing to its complex pharmacological profile. The compound undergoes hepatic metabolism to 7-hydroxymitragynine, a more potent opioid receptor agonist.

Scientific Research

Clinical evidence is limited to a single phase 1 safety study (n=15 healthy volunteers) testing 5-40mg doses, which found no serious adverse events but minor vital sign changes. No RCTs, meta-analyses, or larger trials on efficacy for pain, withdrawal, or other therapeutic uses have been conducted. Most evidence remains preclinical, suggesting analgesic potential and reduced drug self-administration in animal models.

Clinical Summary

Human clinical evidence for mitragynine remains extremely limited, with only one phase 1 safety trial conducted in healthy volunteers. This small study (n=12) showed slight increases in impulsivity measures but no serious adverse events at single doses up to 44.1mg. No controlled trials have evaluated mitragynine for pain management or opioid withdrawal despite extensive preclinical research. Most evidence comes from observational studies and case reports of kratom use rather than isolated mitragynine research.

Nutritional Profile

Mitragynine is the principal indole alkaloid of Kratom (Mitragyna speciosa), typically comprising 12–66% of total leaf alkaloid content. A dried kratom leaf contains roughly 1–2% total alkaloids by weight, with mitragynine concentrations ranging from approximately 5–20 mg per gram of dried leaf depending on strain and origin. It is a terpenoid indole alkaloid (molecular formula C₂₃H₃₀N₂O₄, MW 398.5) and acts primarily as a partial agonist at mu-opioid receptors and an antagonist/weak partial agonist at delta- and kappa-opioid receptors. It also interacts with adrenergic (alpha-2), serotonergic (5-HT₂A, 5-HT₂C), and dopaminergic pathways. Oral bioavailability in animal models is estimated at approximately 20–30%, with extensive first-pass hepatic metabolism via CYP3A4 and CYP2D6 to yield the more potent metabolite 7-hydroxymitragynine. It contains no meaningful macronutrients, vitamins, minerals, fiber, or protein. Plasma half-life in humans is estimated at approximately 23–24 hours based on limited phase 1 data.

Preparation & Dosage

Clinically studied doses in the phase 1 trial were single oral administrations of 5mg, 10mg, 20mg, and 40mg of pure mitragynine, with peak plasma concentrations of ~5.7-25.6 ng/mL at 1 hour. No data exists on repeated dosing, extracts, powders, or standardization in human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Magnesium glycinate (200–400 mg) may help potentiate analgesia and reduce potential tolerance development, as magnesium acts as an NMDA receptor antagonist that can modulate opioidergic signaling. Agmatine sulfate (500–1,000 mg) similarly blocks NMDA receptors and may attenuate tolerance to mu-opioid receptor agonists, complementing mitragynine's partial agonist activity. Curcumin with piperine (500 mg curcumin + 5–10 mg piperine) may inhibit CYP3A4-mediated metabolism, potentially increasing mitragynine bioavailability, while curcumin's own anti-inflammatory action (NF-κB inhibition) may complement analgesic effects. Black seed oil (Nigella sativa, ~1 tsp providing thymoquinone ~5–10 mg) has demonstrated opioid-sparing properties in preliminary research via its own anti-inflammatory and analgesic pathways. Caution: these synergies are theoretical, based on mechanistic pharmacology; CYP enzyme inhibition combinations in particular carry safety risks and should not be attempted without medical supervision.

Safety & Interactions

Mitragynine may cause dose-dependent side effects including nausea, constipation, dizziness, and sedation similar to other opioid receptor agonists. The compound is metabolized by CYP3A4 enzymes, creating potential for drug interactions with CYP3A4 inhibitors or inducers. Regular use may lead to tolerance and physical dependence, with withdrawal symptoms reported upon discontinuation. Safety during pregnancy and breastfeeding has not been established, and use should be avoided in these populations.